MEDICREA: Third-Quarter Sales up +22%

LYON, France & NEW YORK

The MEDICREA group (Alternext Paris: FR0004178572 – ALMED, PEA-PME eligible), which specializes in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, announces its sales for the 3^rd quarter ending September 30, 2015.

Sales totaled €7.1 million over the third quarter of 2015, up +22% on the same quarter of 2014 (+12% at constant currency).

“We have recorded a fine third quarter, which saw an acceleration in our sales on new export markets. In France, driven by the growing interest expressed in our technologies by many surgeons, we are continuing to increase our market share. Sales in the United States, our priority market, accounted for 63% of total sales over the quarter. We are investing heavily in both commercial means and marketing tools in order to accelerate our development and strengthen our leadership position in personalized spine surgery”, says Denys SOURNAC, Chairman and CEO of MEDICREA.

Outlook:

From October 14 to 17, the Group will participate in the NASS (North American Spine Society) congress in Chicago, the world’s largest event for spine professionals, during which it will present its proprietary customized implant technologies, and in particular those relating to UNiD™ osteosynthesis rods that are pre-contoured and specifically customized for each patient, to surgeons from the United States and elsewhere around the world.

In Europe, the first implants manufactured using a 3D printer should be marketed in early 2016.

Next publication: 2015 annual sales, on January 13, 2016 (after market).

About MEDICREA (www.medicrea.com)

The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a $10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

MEDICREA has also become a pioneer and global leader in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod) and lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) that are made to measure by a 3D printer.

The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.

ISIN: FR 0004178572 – Ticker: ALMED

View source version on businesswire.com: http://www.businesswire.com/news/home/20151008006581/en/

MEDICREA
Denys Sournac, +33 (0)4 72 01 87 87
Founder, Chairman and CEO
dsournac@medicrea.com
or
Fabrice Kilfiger, +33 (0)4 72 01 87 87
Chief Financial Officer
fkilfiger@medicrea.com
or
MEDIA
Erich Sandoval for MEDICREA, +1 917-497-2867
esandoval@lazarpartners.com
or
NewCap.
Investor Relations & Strategic Communications
Tristan Roquet Montégon, +33 (0)1 44 71 00 16
medicrea@newcap.fr